BALDO LANCE 4
4 · Adaptive Biotechnologies Corp · Filed Jan 29, 2021
Insider Transaction Report
Form 4
BALDO LANCE
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-01-27$7.80/sh+40,000$312,000→ 40,000 total - Sale
Common Stock
2021-01-27$58.22/sh−17,499$1,018,792→ 22,501 total - Sale
Common Stock
2021-01-27$60.01/sh−8,268$496,163→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-01-27−40,000→ 341,250 totalExercise: $7.80Exp: 2029-05-06→ Common Stock (40,000 underlying) - Sale
Common Stock
2021-01-27$59.24/sh−14,233$843,163→ 8,268 total
Footnotes (5)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020.
- [F2]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.69 to 58.655, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F3]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.715 to 59.60, inclusive.
- [F4]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.715 to 60.43, inclusive.
- [F5]The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested.